Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

An increase in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiotics fosfomycin, pivmecillinam, and nitrofurantoin and the parenteral antibiotic ertapenem. Susceptibility rates indicate that fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) could be considered important oral treatment options.

Knowledge Graph

Similar Paper

Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli
Antimicrobial Agents and Chemotherapy 2010.0
Oral and Parenteral Therapeutic Options for Outpatient Urinary Infections Caused byEnterobacteriaceaeProducing CTX-M Extended-Spectrum β-Lactamases
Antimicrobial Agents and Chemotherapy 2009.0
Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units
Antimicrobial Agents and Chemotherapy 2008.0
Surveillance of Community-Based Reservoirs Reveals the Presence of CTX-M, Imported AmpC, and OXA-30 β-Lactamases in Urine Isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. Community
Antimicrobial Agents and Chemotherapy 2008.0
Urine Bactericidal Activity against Escherichia coli Isolates Exhibiting Different Resistance Phenotypes/Genotypes in an In Vitro Pharmacodynamic Model Simulating Urine Concentrations Obtained after Oral Administration of a 400-Milligram Single Dose of Cefditoren-Pivoxil
Antimicrobial Agents and Chemotherapy 2008.0
Prevalence of Fosfomycin Resistance among CTX-M-Producing Escherichia coli Clinical Isolates in Japan and Identification of Novel Plasmid-Mediated Fosfomycin-Modifying Enzymes
Antimicrobial Agents and Chemotherapy 2010.0
Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)
Antimicrobial Agents and Chemotherapy 2010.0
Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)
Antimicrobial Agents and Chemotherapy 2010.0
Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model
Antimicrobial Agents and Chemotherapy 2007.0
Persistence of Uropathogenic Escherichia coli in the Face of Multiple Antibiotics
Antimicrobial Agents and Chemotherapy 2010.0